1. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413–420 (1995).
2. W. Chi-Yuan, and L. Z. Benet. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res.
22:11–23 (2005).
3. E. H. Kerns, and L. Di. Multivariate pharmaceutical profiling for drug discovery. Curr. Top. Med. Chem. 2:87–98 (2002).
4. Food and Drug Administration. Guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, Food and Drug Administration, Rockville, MD, 2000. Available at
http://www.fda.gov/cder/guidance/index.htm
.
5. World Health Organization. Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediate-release, solid oral dosage forms. World Health Organization, Technical Report Series no. 937 (2006). Available at
http://www.who.int/prequal/info_general/documents/TRS937/WHO_TRS_937__annex8_eng.pdf